Vaxcyte

SutroVax, located in San Francisco, USA, formerly known as SutroVax, is a vaccine research and development company. The company aims to improve global health by developing novel vaccines to prevent or treat some of the most common and deadly infectious diseases worldwide. The company’s cell-free protein synthesis platform includes the XpressCFTM platform (exclusively licensed from Sutro Biopharma, Inc.) and Vaxcyte's proprietary patented technology, enabling the design and production of protein carriers and antigens — key components of vaccines.SutroVax’s lead vaccine candidate, SVX-24, is a preclinical 24-valent pneumococcal conjugate vaccine (PCV) that includes 11 additional strains beyond the 13 strains in Pfizer's current standard Prevnar 13®, including strains that cause high mortality rates, antibiotic resistance, and/or meningitis. Currently, SutroVax is also leveraging its proprietary platform to develop other novel vaccines, including a preventive vaccine for Group A Streptococcus infections and a therapeutic vaccine for periodontal disease.